The HEAL-S study is a non-interventional study with retrospective data analysis. It consists of two parts. First a retrospective analysis based on nucleic acid testing (NAT) results will be performed. Two cohorts (HCV) and (HBV) will be established. Patients falling into one (or both) of the two cohorts will be invited to a prospective linkage-to-care study. In this part, patients are invited to the clinic, where the possibility of hepatitis treatment will be discussed.
The target population for the HCV cohort consists of individuals with detectable plasma HCV RNA at the latest observation.
The target population for the HBV cohort consists of individuals with detectable plasma HBV RNA at any time and no recorded HDV testing or a positive HDV serology.
No valid SVRN (german: Sozialversicherungsnummer, english: Social insurance number)
No contact details available
Documented Sustained Virological Response (HCV cohort)
Documented assessment of HDV status (HBV cohort)
Vanessa Stadlbauer-Koellner, MD
Lead sponsor
Medical University of Graz
Sponsor institution
Medical University of Graz
Collaborator